A claim people encounter online
"BPC-157 is FDA-approved now because FDA reviewed it or because a phase 2 trial exists."
Verdict: Not FDA-approved
BPC-157 is not an FDA-approved drug. FDA compounding review and a recruiting phase 2 trial are real developments, but neither one is a marketing approval.
Why it feels believable
Headlines compress several different processes - advisory review, clinical trial registration, and approval - into a single idea that the government is 'looking at it.'
The short correction
BPC-157 is not an FDA-approved drug. FDA compounding review and a recruiting phase 2 trial are real developments, but neither one is a marketing approval.
Evidence review
What the claim leaves out
ClinicalTrials.gov shows a recruiting phase 2 hamstring study with no posted results.
FDA's safety materials identify limited information and potential immunogenicity, impurity, and characterization concerns.
An advisory committee recommendation or agency review is not a final approved indication or prescribing label.
What evidence would change the answer?
- A completed FDA application review
- An approval letter
- FDA-approved prescribing information
- A clearly defined indication and product
A safer next step
Check Drugs@FDA or an FDA approval announcement rather than a seller page. For an injury, use licensed clinical assessment and established rehabilitation pathways.
Questions this claim raises
Does a registered phase 2 study mean FDA endorses the treatment?
No. Registration makes a planned study visible. It does not mean the intervention has been shown effective or approved.
Can FDA discuss compounding and still not approve the drug?
Yes. Compounding policy review and new-drug approval are different legal and scientific processes.
Related peptide guides
Sources
- 1. Bulk drug substances that may present significant safety risks
U.S. Food and Drug Administration - Accessed 2026-08-04
- 2. BPC 157 for acute hamstring muscle strain repair
ClinicalTrials.gov - Accessed 2026-08-04
- 3. FDA briefing document for BPC-157-related substances
U.S. Food and Drug Administration - Accessed 2026-08-04
Still unsure how this applies to a general evidence question? Ask Harbor can point you to reviewed material. It cannot diagnose symptoms, recommend a product, or replace a licensed clinician.
Ask Harbor